Drugs / XMT-1592
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04396340 | May 2020 → Sep 2022 | non-small cell lung carcinoma, ovarian cancer | Mersana Therapeutics | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XMT-1592 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04396340 ↗ |
| Known as | Anti-napi2b adc xmt-1592 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315004 ↗ |
| Modality | Other / unclassified | “antibody-drug conjugate (ADC) XMT-1592” NCT04396340 ↗ |
| Route | Intravenous | “XMT-1592 administered as an intravenous infusion” NCT04396340 ↗ |